spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Healthcare Industry News:  STENT Thrombosis 

Devices Interventional Cardiology

 News Release - May 11, 2006

Medtronic Announces Schedule of Activities At EuroPCR

Long-Term Data on Endeavor(TM) Drug-Eluting Coronary Stent to Be Presented During Late Breaking Trials

MINNEAPOLIS--(HSMN NewsFeed)--May 11, 2006--Medtronic, Inc. (NYSE:MDT ) today announced its schedule of major activities for the Paris Course on Revascularization (EuroPCR), which begins May 16 at the Palais des Congres in Paris. On the first day of the meeting, Medtronic's Vascular division will present long-term data on the Endeavor(TM) drug-eluting coronary stent from the ENDEAVOR I and ENDEAVOR II clinical trials. In addition, Medtronic will host physician symposia on chronic total occlusions (CTO) and drug-eluting stent safety, as well as sponsor a variety of case review and educational sessions. The schedule of activities includes the following:

Tuesday, May 16

  • Focus Session: 3 - 5:30 p.m. CEST (Paris time), Room 5. "Learning the techniques: Challenging cases on acute myocardial infarction." Dr. Bernard Chevalier, Paris, France, will chair this session on how to improve revascularisation during percutaneous coronary intervention, including challenging recorded cases from Jagiellonian University, Krakow, Poland. The panel includes Prof. A. Bartorelli, Milan, Italy; Dr. D. Dudek, Krakow, Poland; Dr. E. Garcia, Madrid, Spain; Dr. G. Sianos, Rotterdam, Netherlands; and Dr. H. Suryapranata, Zwolle, Netherlands.
  • Late Breaking Trials - Clinical Trial Update: 5:35 - 5:55 p.m. CEST, Room 1. Dr. William Wijns, Aalst, Belgium, and Dr. Philippe Urban, Geneva, Switzerland, will co-chair this EuroPCR Late Breaking Trials session, during which time long-term data on the Endeavor drug-eluting coronary stent from the ENDEAVOR I and ENDEAVOR II clinical studies will be presented. Prof. Ian Meredith, Melbourne, Australia, will present 36-month clinical results from its first-in-man ENDEAVOR I trial, and 24-month data from the pivotal ENDEAVOR II trial. Medtronic will issue a news release on this data following the presentation (approx. Noon EDT).

Wednesday, May 17

  • Symposium: 4:30 - 6 p.m. CEST, Room 2. "Safe and effective approaches to chronic total occlusions." This 90-minute symposium will provide information on the prevalence and key clinical data surrounding chronic total occlusions, which are severe blockages of blood vessels that often require special medical treatment. The session also includes valuable discussions about how to access a CTO, tools and techniques for treating CTOs, when to start and stop, and how to best manage complications. Chaired by Prof. Eric Eeckhout, Lausanne, Switzerland, the panel also includes Dr. E. Garcia, Madrid, Spain; Dr. S. Carlier, New York, USA; Dr. R. Koning, Rouen, France; Prof. F-X. Kleber, Berlin, Germany; and Dr. J. Koolen, Eindhoven, Netherlands.

Thursday, May 18

  • Symposium: 12 - 1:30 p.m. CEST, Room 1. "Drug-eluting stent safety: challenges and insights." Dr. Jean Fajadet, Toulouse, France, chairs this symposium examining the current evidence surrounding the long-term safety profile of drug-eluting stents, including the most relevant risk factors for late STENT Thrombosis in a real world setting. Also on the panel are Dr. E. Camenzind, Geneva, Switzerland; Dr. R. Virmani, Washington, D.C., USA; Dr. G. Sangiorgi, Rome, Italy; Prof. C. Lotan, Jerusalem, Israel; and Prof. J. Marco, Toulouse, France.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Caution: The Endeavor Drug-Eluting Coronary Stent is an investigational device with an investigational drug (ABT-578) and exclusively for clinical investigation in the United States.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Quarterly Report on Form 10-Q for the quarter ended January 27, 2006. Actual results may differ materially from anticipated results.

Source: Medtronic

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

Search: Medtronic 

 Related News Items

Medtronic Advances Abbott CGM Partnership with FDA Submission of Interoperable Insulin Pump

Medtronic appoints Thierry Piéton as Chief Financial Officer

Medtronic Achieves CE Mark Approval for BrainSense Adaptive Deep Brain Stimulation and Electrode Identifier, a Groundbreaking Advance In Personalized, Sensing-Enabled Care for People with Parkinson's Through Innovative Brain-Computer Interface Technology

Healthcare Industry NewsFeed  


FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.